EXPERIMENTAL STUDY

Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription

Akira Takeshita, Noriyuki Koibuchi1, Junko Oka, Manabu Taguchi, Yoshimasa Shishiba and Yasunori Ozawa
Division of Endocrinology and Metabolism, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo 105-8470, Japan and
1Department of Physiology, Gunma University School of Medicine and CREST, Japan Science and Technology Corporation, Maebashi, Gunma 371-8511, Japan
(Correspondence should be addressed to Akira Takeshita, Division of Endocrinology and Metabolism, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato, Tokyo 105-8470, Japan; Email: coactivator@mac.com)

Abstract

Background: There is increasing concern about endocrine-disrupting chemicals (EDCs) which may produce adverse health effects in humans and other species. One such chemical, bisphenol-A (BPA), a monomer of polycarbonate plastics, is widely used in consumer products; it has been reported to contain estrogenic activity through binding to estrogen receptors. Cytochrome P450 monooxygenase 3A4 (CYP3A4) is one of the key enzymes for the metabolism of endogenous steroids and foreign chemicals in liver. The orphan nuclear receptor, steroid and xenobiotic receptor (SXR/PXR), has recently been isolated. A variety of known inducers of CYP3A4 bind to SXR/PXR, and stimulate transcription on xenobiotic-response elements (XREs) located in the promoter region of the CYP3A4 gene. Recent study has shown that EDCs, diethylhexylphthalate (DEHP) and nonylphenol, but not BPA, induce mouse SXR/PXR-mediated transcription. However, it is known that species differences in SXR alter CYP3A inducibility.

Objective: To test whether BPA stimulates human SXR/PXR-mediated transcription using reporter gene assays.

Methods: Transfection assays were performed with human SXR/PXR expression plasmid and a reporter plasmid containing the XREs in the CYP3A4 gene promoter in HepG2 cells. BPA-induced interaction of human SXR/PXR with steroid receptor coactivator-1 (SRC-1) was analyzed by mammalian two-hybrid assays.

Results: BPA, as well as DEHP, activated human SXR-mediated transcription on the XREs. In mammalian two-hybrid assays, BPA recruited SRC-1 to the ligand-binding domain of human SXR/PXR.

Conclusions: Our observations have indicated that BPA may be a human-specific inducer of the CYP3A4 gene, and may influence the metabolism of endogenous steroids, drugs, and other xenobiotics.

European Journal of Endocrinology 145 513–517

Introduction

There is increasing concern about endocrine-disrupting chemicals (EDCs) which may produce adverse health effects in humans and other species. One such chemical, bisphenol-A (BPA), a monomer of polycarbonate plastics, is widely used in consumer products. For instance, a significant amount of BPA is released into food and human saliva from the inner coating of food cans (1) and dental composites (2) respectively. BPA has a high homology with diethylstilbestrol (DES), a synthetic substance with potent estrogenic activity. Although the affinities of BPA to human estrogen receptor (ER) α and β are much lower than those of estradiol and DES, BPA binds to the ERs and stimulates transcription (3), indicating that BPA may act as an environmental estrogen. In fact, BPA induces progesterone receptor expression in the ER-positive human breast cancer cell line, MCF-7 cells, and also increases its proliferation (4).

The cytochrome P450 (CYP) superfamily consists of heme-containing mono-oxygenases which play an important role in the oxidative metabolism of endogenous substances, natural compounds, and xenobiotics. The CYP mono-oxygenase 3A4 (CYP3A4) gene product is the most abundant CYP that is expressed in human liver and it is involved in the metabolism of most drugs, a variety of endogenous steroids, and environmental procarcinogens (5). The expression of CYP3A4 is transcriptionally activated by many natural
and xenobiotic compounds. For instance, the antibiotic rifampicin is a well-known inducer of the human CYP3A4 gene. Recently, the orphan nuclear receptor, steroid and xenobiotic receptor (SRX) (also called pregnane X receptor (PXR)), has been isolated (6–9). A variety of known inducers of CYP3A4 bind to SRX/PXR, and stimulate transcription on xenobiotic-response elements (XREs), located in the promoter region of the CYP3A4 gene (6–10).

The SRX/PXR-mediated transactivation by EDCs has recently been reported (11). Diethylhexylphthalate (DEHP) and nonylphenol, but not BPA, induce mouse SRX/PXR-mediated transcription (11). However, there are markedly different activation profiles in response to xenobiotics among species (7, 8). For instance, rifampicin is a strong agonist in human and rabbit SRX/PXR, but not in rat and mouse SRX/PXR (12). The differences in xenobiotic actions among species are likely due to differences in the structure of SRX/PXR. Human and mouse SRX/PXR share only 77% amino acid identity in their ligand-binding domain (LBD), whereas they share 96% identity in the DNA-binding domain (DBD) (12). Thus, human SRX/PXR may possess different inducibility from mouse SRX/PXR by EDCs.

In the present study, we tested whether BPA stimulates human SRX/PXR-mediated transcription to induce the CYP3A4 gene.

Materials and methods

Reagents and chemicals

Rifampicin, corticosterone, and DEHP were obtained from Sigma Chemical Co. (St Louis, MO, USA). BPA was from Wako Pure Chemical Industries Ltd (Osaka, Japan).

Plasmids

Human SRX in pCDG1 was kindly provided by Dr R M Evans, Salk Institute, La Jolla, CA, USA (8). A schematic diagram of GAL4 or VP16 fusion constructs used is shown in Fig. 1. GAL4 SRX-LBD and GAL4 SRC-1-RID were constructed by ligating the LBD of human SRX (amino acids 107–434) and nuclear receptor interacting domain (RID) containing three LXXLL motifs in human steroid receptor coactivator-1 (SRC-1) (amino acids 595–780) (13) into the GAL4 DBD in the pM expression vector (Clontech, Palo Alto, CA, USA) respectively. VP16 SRX-LBD and VP16 SRC-1-RID were constructed by ligating the same amino acid fragments of SRX and SRC-1 in GAL4 SRX-LBD and GAL4 SRC-1-RID into downstream of the VP16 activation domain in AAV-VP16 (kindly provided by Dr S M Weissman, Yale School of Medicine, New Haven, CT, USA) (14) respectively. The chimeric CYP3A4 luciferase (LUC)
reporter construct, a xenobiotic-responsive enhancer module (XREM)-CYP3A4-LUC, containing the enhancer (nucleotides -7836 to -7208) and promoter (nucleotides -362 to +53) of human CYP3A4 driving luciferase expression, was kindly provided by Dr S A Kliewer, Glaxo Wellcome Research and Development, Research Triangle Park, NC, USA (10, 15). The LUC reporter construct, 5×upstream activating sequence (UAS)-thymidine kinase minimum promoter (TK)-LUC, was kindly provided by Dr A N Hollenberg, Beth Israel Deaconess Medical Center, Boston, MA, USA (16).

**Transient cotransfection experiments**

HepG2 cells or CV-1 cells were grown in Dulbecco’s modified Eagle’s medium and 5% fetal calf serum. The serum was stripped of hormones by constant mixing with 5% (w/v) AG1-X8 resin (Bio-Rad, Hercules, CA, USA) and powdered charcoal before ultrafiltration. The cells were maintained without antibiotics. Cells were transiently transfected using the calcium phosphate coprecipitation method in six-well plates with 1.5 μg reporter plasmid containing XREM-CYP3A4-LUC or 5×UAS-TK-LUC cDNA with expression vectors as indicated in the Figure legends. CMV-β-galactosidase plasmid was used as an internal control. In some samples, empty expression vectors were added to equalize total transfected plasmid concentration. Cells were grown for 24 h in the absence or presence of ligand, and then harvested. Cell extracts were analyzed for both luciferase and β-galactosidase activity in order to correct for transfection efficiency as previously described (17). The corrected luciferase activities of untreated samples were normalized to the luciferase activities of samples as described in the Figure legends. All transfection studies were repeated at least twice in triplicate. The results shown are the means ± s.d. (n = 3).

**Results**

To determine whether BPA stimulates human SXR/PXR-mediated transcription, transient transfection assays were performed with human SXR/PXR expression plasmid and a reporter plasmid, XREM-CYP3A4-LUC, containing the enhancer and promoter of CYP3A4 driving luciferase gene expression (10, 15) in a human liver-derived cell line, HepG2 (Fig. 2). Unlike the mouse SXR/PXR system (11), human SXR/PXR-mediated transcription was stimulated by BPA on the CYP3A4 gene. Thus, induction of the CYP3A4 gene by BPA was species-specific. DEHP treatment showed similar transcriptional efficacy. Of note, compared with rifampicin and corticosterone, which were efficacious activators of human SXR/PXR, these two EDCs had significant effects only at a high concentration (>1 μM).

Transcriptional activation by nuclear hormone receptors (NRs) is mediated by ligand-dependent interaction with coactivators. SRC-1 belongs to a 160 kDa subset of the nuclear receptor coactivator family that includes TIF2/GRIP1 and TRAM-1/AIB1/RAC3/ACTR (18, 19). SRC-1 binds to a variety of NRs in a ligand-dependent manner and enhances ligand-induced transcriptional activity of NRs. To determine whether BPA increases the interaction of human SXR/PXR with SRC-1, mammalian two-hybrid assays were performed. As illustrated in Fig. 1, the LBD of human SXR/PXR was fused to the DBD of GAL4 (GAL4 SXR-LBD), and the RID of SRC-1 containing three LXXLL motifs was fused to the transactivation domain of VP16 (VP16 SRC-1-RID). These constructs were cotransfected with a reporter plasmid containing five copies of a GAL4 UAS (5×UAS-TK-LUC) in CV-1 cells. When the transfection was performed with a combination of GAL4 SXR-LBD and VP16 SRC-1-RID, both rifampicin and BPA strongly enhanced the reporter activities, compared with a combination of GAL4 SXR-LBD and empty VP16 vector (Fig. 3A). The assay was also performed using the opposite configuration (Fig. 3B). GAL4 SRC-1-RID interacted with VP16 SXR-LBD in the presence of rifampicin and BPA. Similar results were obtained when we used HepG2 cells, instead of CV-1 cells. These mammalian two-hybrid assays indicated that BPA, as well as rifampicin, recruits SRC-1 to the LBD of human SXR/PXR.

**Discussion**

Previous studies have emphasized only the estrogenic activity of BPA (20). We have here shown another

---

**Figure 2** BPA stimulates human SXR-mediated transcription on the CYP3A4 promoter. The expression plasmid containing human SXR (0.1 μg) and the reporter plasmid XREM-CYP3A4-LUC (1.5 μg) were cotransfected with CMV-β-galactosidase control vector (0.1 μg) in HepG2 cells. Cells were treated with several compounds for 24 h and analyzed for luciferase activity. Luciferase activity was normalized to β-galactosidase activity and then calculated as fold luciferase activity with 1-fold basal activity defined as the luciferase activity with human SXR in the absence of the ligand. The results are expressed as means ± s.d. (n = 3). Dose–response analysis was performed with rifampicin, corticosterone, DEHP, and BPA.
function of BPA as a ligand of human SXR/PXR. BPA activates human SXR on a reporter gene containing XREs in the CYP3A4 gene promoter. The response to BPA is mediated by the LBD of human SXR, which contains ligand-dependent transactivation domain (AF-2). In addition, BPA recruits SRC-1, a nuclear receptor coactivator, to the LBD of human SXR. Since CYP3A4 plays a critical role in the catalysis of steroid hormones, BPA may influence the metabolism of endogenous steroids such as corticosteroids and gonadal steroids in adults, children, and fetuses.

The induction of CYP3A expression by xenobiotics is quite different between humans and rodents (5, 7, 8). Recent studies have revealed that divergent structural differences in the LBD of SXR/PXR causes marked pharmacological differences in SXR/PXR activation profiles (12). Although BPA failed to induce mouse SXR/PXR-mediated transcription in a previous report (11), it stimulated human SXR/PXR-mediated transcription in the present study. Thus, the effects of EDCs on CYP3A expression are species-specific. Xie et al. (21) created a humanized xenobiotic response in mice by replacing with the human SXR/PXR gene. Such an approach will be useful in addressing the effects of EDCs on human CYP3A expression.

Whether a low dose of exposure to environmental agents can influence human endocrine functions is a common concern about all EDCs. In our in vitro reporter assay, both BPA and DEHP induced human SXR/PXR-mediated transcription only at high concentrations. Although these EDCs showed low potencies in vitro, we suggest several possibilities that BPA and/or DEHP may function as EDCs to influence human SXR-mediated transcription in vivo. First, the potency of an in vitro reporter assay may be less than that of the situation in vivo. Steinmetz et al. (22) studied the estrogenic potency of BPA in vivo and in vitro. They observed that BPA had a similar efficacy to estradiol in inducing hyperprolactinomas in F344 rats, while BPA was 1000- to 5000-fold less active than estradiol in vitro. Secondly, combinations of BPA with other xenobiotics such as DEHP may additively activate human SXR/PXR. To support this hypothesis, BPA was detected along with DEHP, nonylphenol, and di-nbutylphthalate in dialysate in plastic dialysis bags (23). In addition, Blumberg et al. (8) reported that the cocktails of endogenous steroids additively increase human SXR-mediated transcription. Thirdly, we may be exposed to significant amounts of BPA and/or DEHP. For instance, 90–931 μg BPA was detected in the
saliva of patients treated with dental sealants (2), and 1.3–17200 μg/l BPA with a median concentration of 269 μg/l in hazardous waste landfill leachates was collected in Japan (24). As much as 44.3–197.1 mg DEHP was extracted from the dialyzer during a single dialysis session (25). Therefore, BPA and/or DEHP may influence human CYP3A expression in certain circumstances.

We have not tested other environmental estrogens such as polychlorinated hydroxybiphenyls, DDT and its derivatives, and phthoestrogens. It will be important to know whether those xenoestrogens activate human SXR/PXR.

In summary, our study suggests that BPA, as well as DEHP, acts as a ligand of human SXR/PXR. BPA may be a human-specific inducer of the CYP3A4 gene, and may potentially influence the metabolism of endogenous steroids, drugs, and other xenobiotics.

Acknowledgements

We thank Drs S M Weissman, R M Evans, A N Hollenberg, and S A Kliewer for providing plasmids and H Sato (Dokkyo University, Japan) for helpful discussion.

References


Received 23 January 2001
Accepted 8 May 2001